| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
4,610,000 |
| Market
Cap: |
21.30(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.945 - $11.02 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kala Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for diseases of the eye. Co.'s two marketed products are EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25%, for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease, and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1%, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Co. is also progressing its pipeline of proprietary programs targeted to address front and back of the eye diseases, including KPI-287 and glucocorticoid receptor modulators.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
310,559 |
310,559 |
310,559 |
| Total Buy Value |
$0 |
$2,000,000 |
$2,000,000 |
$2,000,000 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
1 |
1 |
| Total Shares Sold |
63,067 |
77,012 |
77,012 |
136,547 |
| Total Sell Value |
$244,154 |
$350,555 |
$350,555 |
$674,069 |
| Total People Sold |
5 |
5 |
5 |
6 |
| Total Sell Transactions |
11 |
16 |
16 |
32 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Reumuth Mary |
CHIEF FINANCIAL OFFICER |
• – – |
2025-06-24 |
4 |
AS |
$4.01 |
$14,560 |
D/D |
(3,631) |
62,100 |
|
16% |
|
| Brazzell Kim |
SEE REMARKS |
• – – |
2025-06-24 |
4 |
AS |
$4.01 |
$21,057 |
D/D |
(5,251) |
82,698 |
|
16% |
|
| Iwicki Mark T |
|
– • – |
2025-06-24 |
4 |
AS |
$4.01 |
$53,040 |
D/D |
(13,227) |
258,433 |
|
16% |
|
| Bazemore Todd |
SEE REMARKS |
• – – |
2025-06-24 |
4 |
AS |
$4.01 |
$16,273 |
D/D |
(4,058) |
83,699 |
|
16% |
|
| Kharabi Darius |
CHIEF BUSINESS OFFICER |
• – – |
2025-06-24 |
4 |
AS |
$4.01 |
$18,089 |
D/D |
(4,511) |
62,566 |
|
16% |
|
| Farid Marjan |
|
– • – |
2025-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,450 |
10,242 |
|
- |
|
| Koven Andrew I |
|
– • – |
2025-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,050 |
16,972 |
|
- |
|
| Perry Gregory D |
|
– • – |
2025-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,450 |
13,344 |
|
- |
|
| Rosen Howard B |
|
– • – |
2025-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,450 |
16,240 |
|
- |
|
| Myers C. Daniel |
|
– • – |
2025-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,450 |
10,374 |
|
- |
|
| Iwicki Mark T |
|
– • – |
2025-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,450 |
271,660 |
|
- |
|
| Iwicki Mark T |
Director |
– • – |
2025-06-03 |
4/A |
AS |
$3.74 |
$40,639 |
D/D |
(10,866) |
269,210 |
|
- |
|
| Kharabi Darius |
CHIEF BUSINESS OFFICER |
• – – |
2025-06-03 |
4 |
AS |
$3.74 |
$2,730 |
D/D |
(730) |
67,077 |
|
13% |
|
| Reumuth Mary |
CHIEF FINANCIAL OFFICER |
• – – |
2025-06-03 |
4 |
AS |
$3.74 |
$10,659 |
D/D |
(2,850) |
65,731 |
|
13% |
|
| Iwicki Mark T |
|
– • – |
2025-06-03 |
4 |
S |
$3.74 |
$40,639 |
D/D |
(10,866) |
269,210 |
|
-13% |
|
| Brazzell Kim |
SEE REMARKS |
• – – |
2025-06-03 |
4 |
AS |
$3.74 |
$13,789 |
D/D |
(3,687) |
87,949 |
|
13% |
|
| Bazemore Todd |
SEE REMARKS |
• – – |
2025-06-03 |
4 |
AS |
$3.74 |
$12,679 |
D/D |
(3,390) |
87,757 |
|
13% |
|
| Reumuth Mary |
CHIEF FINANCIAL OFFICER |
• – – |
2025-01-06 |
4 |
AS |
$7.63 |
$13,017 |
D/D |
(1,706) |
68,581 |
|
-51% |
|
| Reumuth Mary |
CHIEF FINANCIAL OFFICER |
• – – |
2025-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
10,100 |
70,287 |
|
- |
|
| Iwicki Mark T |
CHIEF EXECUTIVE OFFICER |
• • – |
2025-01-06 |
4 |
AS |
$7.63 |
$44,094 |
D/D |
(5,779) |
280,076 |
|
-51% |
|
| Iwicki Mark T |
CHIEF EXECUTIVE OFFICER |
• • – |
2025-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
22,100 |
285,855 |
|
- |
|
| Bazemore Todd |
SEE REMARKS |
• – – |
2025-01-06 |
4 |
AS |
$7.63 |
$15,207 |
D/D |
(1,993) |
0 |
|
-51% |
|
| Bazemore Todd |
SEE REMARKS |
• – – |
2025-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
10,100 |
0 |
|
- |
|
| Kharabi Darius |
CHIEF BUSINESS OFFICER |
• – – |
2025-01-06 |
4 |
AS |
$7.63 |
$15,420 |
D/D |
(2,021) |
67,807 |
|
-51% |
|
| Kharabi Darius |
CHIEF BUSINESS OFFICER |
• – – |
2025-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
10,100 |
69,828 |
|
- |
|
188 Records found
|
|
Page 1 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.64 (12.08%) 
